ONO-2506PO

Phase 2Completed

2 views this week 0 watching💤 Quiet

Interest: 35/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Parkinson's Disease

Conditions

Parkinson's Disease

Trial Timeline

Jan 1, 2004 → —

NCT ID

NCT00212693

About ONO-2506PO

ONO-2506PO is a phase 2 stage product being developed by Ono Pharmaceutical for Parkinson's Disease. The current trial status is completed. This product is registered under clinical trial identifier NCT00212693. Target conditions include Parkinson's Disease.

What happened to similar drugs?

20 of 20 similar drugs in Parkinson's Disease were approved

Approved (20) Terminated (3) Active (0)

✅Lemborexant + placeboEisaiApproved

✅Levodopa-carbidopa intestinal gel (LCIG)AbbVieApproved

✅Carbidopa/levodopa/entacaponeNovartisApproved

✅Carbidopa/levodopa/entacapone + Immediate release carbidopa/levodopaNovartisApproved

✅carbidopa/levodopa + Carbidopa/Levodopa/EntacaponeNovartisApproved

✅carbidopa, levodopa, entacaponeNovartisApproved

✅Levodopa/carbidopa/entacapone + Levodopa/carbidopaNovartisApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (3)

NCT ID	Phase	Status	Start	Completion	Indication
NCT00694941	Phase 2	Completed	Jun 1, 2008	—	Amyotrophic Lateral Sclerosis (ALS)
NCT00083421	Phase 2	Completed	Jun 1, 2004	Jul 1, 2007	Alzheimer's Disease
NCT00212693	Phase 2	Completed	Jan 1, 2004	—	Parkinson's Disease

Competing Products

20 competing products in Parkinson's Disease

See all competitors

Product	Company	Stage	Hype Score
UB-312 + Placebo	Vaxxinity	Phase 1	19
NAV5001 + DaTscan	Navidea Biopharmaceuticals	Phase 3	22
piclozotan + 0.9% sodium chloride (normal saline)	Daiichi Sankyo	Phase 2	35
E2007	Eisai	Phase 3	32
ARICEPT	Eisai	Phase 3	40
Perampanel	Eisai	Phase 3	32
GPI 1485	Eisai	Phase 2	35
E2007	Eisai	Phase 3	40
Prior Donepezil 5mg + Prior Donzepezil 10mg + Prior Placebo	Eisai	Phase 3	40
perampanel + placebo	Eisai	Phase 2	27
Lemborexant + placebo	Eisai	Approved	50
Placebo + E2007 + E2007	Eisai	Phase 3	32
E2007 + E2007 + E2007	Eisai	Phase 2	35
E2007	Eisai	Phase 2	35
E2007	Eisai	Phase 2	27
E2007	Eisai	Phase 2	27
2 mg perampanel + 4 mg perampanel + placebo comparator	Eisai	Phase 3	40
Istradefylline (KW-6002)	Kyowa Kirin	Phase 2	35
Istradefylline 20 mg or 40 mg	Kyowa Kirin	Phase 3	40
Istradefylline (KW-6002)	Kyowa Kirin	Phase 3	40